Literature DB >> 22789300

High incidence of upper-extremity deep vein thrombosis with dual-lumen venovenous extracorporeal membrane oxygenation.

Alexis E Shafii1, Chase R Brown, Sudish C Murthy, David P Mason.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22789300     DOI: 10.1016/j.jtcvs.2012.06.028

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


× No keyword cloud information.
  4 in total

1.  Venous Thromboembolism After Adult Lung Transplantation: A Frequent Event Associated With Lower Survival.

Authors:  Manuel L Ribeiro Neto; Marie Budev; Daniel A Culver; C Randall Lane; Marcelo Gomes; Xiao-Feng Wang; Paulo Novis Rocha; Mitchell A Olman
Journal:  Transplantation       Date:  2018-04       Impact factor: 4.939

2.  Veno-Venous Extracorporeal Membrane Oxygenation (VV ECMO) for Acute Respiratory Failure Following Injury: Outcomes in a High-Volume Adult Trauma Center with a Dedicated Unit for VV ECMO.

Authors:  Jay Menaker; Ronald B Tesoriero; Ali Tabatabai; Ronald P Rabinowitz; Christopher Cornachione; Terence Lonergan; Katelyn Dolly; Raymond Rector; James V O'Connor; Deborah M Stein; Thomas M Scalea
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

3.  Runtime and aPTT predict venous thrombosis and thromboembolism in patients on extracorporeal membrane oxygenation: a retrospective analysis.

Authors:  Franziska C Trudzinski; Peter Minko; Daniel Rapp; Sebastian Fähndrich; Hendrik Haake; Myriam Haab; Rainer M Bohle; Monika Flaig; Franziska Kaestner; Robert Bals; Heinrike Wilkens; Ralf M Muellenbach; Andreas Link; Heinrich V Groesdonk; Christian Lensch; Frank Langer; Philipp M Lepper
Journal:  Ann Intensive Care       Date:  2016-07-19       Impact factor: 6.925

Review 4.  Protocol-driven daily optimisation of venovenous extracorporeal membrane oxygenation blood flows: an alternate paradigm?

Authors:  Kiran Shekar; Hergen Buscher; Daniel Brodie
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.